GTX-RT in Borderline Resectable Pancreatic Cancer

NCT01754623 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Lack of pre-treatment tissue to make the study plan feasible.

Conditions

Pancreatic Cancer

Interventions

DRUG: Capecitabine
DRUG: Gemcitabine
DRUG: Docetaxel
RADIATION: Stereotactic body radiation therapy (SBRT)
OTHER: Restaging review after radiation
PROCEDURE: Surgery
DRUG: 5-Fluorouracil

Sponsor

H. Lee Moffitt Cancer Center and Research Institute